Home › Companies › NGEN

Pipeline (2 active programs)

Discontinued (2)

• NVG-291 — Spinal Cord Injury · strategic deprioritization; enrollment concluded to focus on chronic tetraplegia registrational study
• NVG-300 — Amyotrophic Lateral Sclerosis · preclinical validation in ALS will not proceed at this time

Biotech Distilled coverage (8)

• 2026-05-22 UPDATE: NervGen Pharma (NGEN) — The Deal Prints. Now You Can See the Cap Table. 🔒 Paid
• 2026-05-21 UPDATE: NervGen Pharma (NGEN) — The Prospectus Hits the Wire
• 2026-05-16 UPDATE: NervGen Pharma (NGEN) — Management Just Put a Date on the Dilution Gap 🔒 Paid
• 2026-04-28 UPDATE: NervGen Pharma (NGEN) — The CFO Watch Item Just Resolved 🔒 Paid
• 2026-04-27 UPDATE: NervGen Pharma (NGEN) - The Sarepta Playbook Worked 🔒 Paid
• 2026-03-07 UPDATE: NervGen (NGEN): Adopting the Sarepta Playbook Ahead of FDA Negotiations 🔒 Paid
• 2026-02-14 UPDATE: NervGen Pharma (NGENF): A C-Suite Shuffle on the Edge of the Dilution Gap
• 2026-01-14 NervGen Pharma (NGENF): Scientific Deep Dive for NVG-291 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.